Choksi Laboratories Ltd.
Snapshot View

15.00 +0.70 ▲4.9%

26 July 2021, 04:00:00 P.M.
Volume: 19,224

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Compare with Industry peers
Website http://www.choksilab.com
Financial Indicators
Market Cap 10.45 Cr.
Earnings per share (EPS) -3.74 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-03
Industry PE 225.80 Trailing Twelve Months Ending 2021-03
Book Value / Share 25.48 Trailing Twelve Months Ending 2021-03
Price to Book Value 0.59 Calculated using Price: 15.00
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 0.70 Cr. 6,965,263 Shares
FaceValue 10
Company Profile

Established in 1982, Choksi Laboratories Limited (CLL), is more widely known as a leading analysis and research group, providing complete solutions for improving quality in processes, products and services.

CLL is a contract testing and analysis laboratory based in Indore, Central India. It analyzes, for its clients, or as a regulatory requirement, pharmaceuticals, food and agricultural products, construction materials, chemicals etc. It also help industries in their research processes. Its environment consultancy division helps firms in keeping the environment clean and free from pollution.

CLL was the first to develop Vendor Assessment programme in the edible oil extraction industry. The first to start water and soil analysis in Central India, also the first to start instrument calibration services for organizations that were targeting ISO certification or had already achieved it. The only one to commission and run, probably the largest Effluent Treatment Plant in India, at ONGC's Amod oil rig.

Quality products are a function of better raw materials and quality procedures.  CLL currently has facilities for analysis of over 1000 products and materials, with more being added every day.

A vast updated database of test specifications derived from AOAC, USP, BP, CP, EP, IP, IS, EPA, PFA, Food Chemicals Codex, AOCS, and several in-house methods, serves a wide spectrum of products and materials – pharmaceutical raw materials and formulations, agro products and their derivatives, fertilizers, pesticides, edible and industrial oils, chemicals, paints and dyes.

Last year, CLL provided its services to more than 1,000 customers world-wide. Driving this accelerated growth is a hard-working people-force of 200+ CLL personnel. They are young (The average age in CLL is below 30 years). They are determined. And they have a huge appetite for learning. Mostly from the University town of Indore, these graduates undergo a rigorous six month training at their lab. Once inducted, continuous training programmes take over - both internal as well as external. And finally the long painful process of getting these qualified personnel approved as FDA, BIS, MoEF - whatever their respective fields demand. In fact, one thing that they are quite known for is their excellent human resource pool. So much so that the surrounding companies keep playing bait to our experienced staff. Though it is quite a nuisance at times, it also does us proud when they are recognized and accepted in regional companies, and multinationals alike.

Services offered by the company:

  • Contract Laboratory Services (CLS):-Pharmaceutical Analysis-Food & Beverages Analysis-Water Analysis-Construction Material Analysis
  • Instrument Calibration & Validation Services
  • Environment Management Services
  • Clinical Research
  • Consultancy  
  • Assaying & Hallmarking

Clientele:

  • IPCA Laboratories
  • Nicholas Piramal India Ltd.
  • Serum Institute of India
  • Famycare India

Achievements/ recognition:

  • CLL is certified by BIS (Bureau of Indian Standards), FDA (Food and Drugs control Administration), MoEF (Ministry of Environment & Forests), State Pollution Control Boards (Gujarat and Madhya Pradesh State Pollution Control Boards), Department of Health(MP), Agricultural Marketing Advisor (AGMARK - GOI), and several other regulatory bodies.
  • CLL has also been accredited by NABL (National Accreditation Board for testing & calibration Laboratories). This is internationally recognized through ILAC (International Laboratory Accreditation Committee) and is based on ISO/IEC 17025 guidelines.
  • ISO/IEC 17025 : 2005Ministry of Environment & Forests (MoEF), India
  • Bureau of Indian Standards (BIS), India
  • Export Inspection Council (EIC), India
  • AGMARK, IndiaGold & Silver Assaying & Hallmarking Center (approved by Bureau of Indian Standards)

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+4.90%
1 Week
+2.18%
1 Month
+17.92%
3 Month
+82.70%
6 Month
+44.23%
1 Year
+66.67%
2 Year
+26.58%
5 Year
-2.34%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 6.15 5.58 5.95 4.45 3.67 4.34 6.19 6.90 -17.57
Return on Capital Employed (%) 10.93 9.59 9.42 9.39 7.32 8.41 10.49 10.14 -8.27
Return on Assets (%) 3.27 3.11 3.19 2.31 1.80 2.15 3.16 3.20 -6.53

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 18 19 20 19 20 21 22 24 20
Non Curr. Liab. 5 6 8 6 9 5 7 18 29
Curr. Liab. 9 10 10 12 14 14 16 13 14
Minority Int.
Equity & Liab. 31 34 39 38 43 41 45 55 64
Non Curr. Assets 21 23 27 23 28 28 30 39 47
Curr. Assets 10 12 11 15 15 13 15 16 17
Misc. Exp. not W/O
Total Assets 31 34 39 38 43 41 45 55 64

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 15 17 20 22 22 29 31 34 28
Other Income 0 0 0 1 0 1 0 0 0
Total Income 16 17 20 23 22 30 32 34 28
Total Expenditure -11 -13 -16 -17 -17 -24 -25 -26 -25
PBIDT 4 4 4 6 5 6 7 8 3
Interest -1 -1 -1 -2 -1 -1 -2 -2 -2
Depreciation -1 -1 -2 -3 -3 -3 -3 -4 -5
Taxation 0 0 0 -1 0 0 -1 -1 2
Exceptional Items -2
PAT 1 1 1 1 1 1 1 2 -4

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 4 2 4 2 7 7 6 7 3
Cash Fr. Inv. -2 -3 -6 -1 -7 -2 -5 -10 -14
Cash Fr. Finan. -2 0 1 -1 1 -5 -1 2 11
Net Change 0 0 -1 0 0 0 0 -1 0
Cash & Cash Eqvt 2 2 1 1 1 1 1 0 0

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 31.48 31.48 31.48 31.48 31.48 31.48 31.48 31.48 31.48
Public 68.52 68.52 68.52 68.52 68.52 68.52 68.52 68.52 68.52
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Thu, 15 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
compliance certificate under reg.74(5) of SEBI DP regulation
Fri, 09 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- sanjay chourey
Designation :- Company Secretary and Compliance Officer
Fri, 09 Jul 2021
Shareholding for the Period Ended June 30 2021
Choksi Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here

Technical Scans View Details

Mon, 26 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index
Increasing Relative Strength - Benchmark index Increasing Relative Strength - Benchmark index
Strongly Outperforming Sectoral Index Strongly Outperforming Sectoral Index

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,769.22 703.40 +1.4%
Divi's Laboratories Ltd. 130,349.05 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. 90,021.63 5,411.25 -0.2%
Cipla Ltd. 76,675.40 950.55 +0.3%
Cadila Healthcare Ltd. 61,992.73 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. 58,965.37 4,100.95 +4.7%
Aurobindo Pharma Ltd. 55,837.02 952.95 -1.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.12 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 65.69 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.13 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 31.88 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 29.06 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 392.16 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.47 952.95 -1.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 14.02 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.14 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 4.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.77 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.83 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.55 952.95 -1.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 952.95 -1.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 952.95 -1.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 952.95 -1.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 952.95 -1.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 952.95 -1.1%